Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Anebulo Pharmaceuticals Inc
Pre-Tax Income
Anebulo Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
Pre-Tax Income
-$11.7m
|
CAGR 3-Years
-310%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$20.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
-$5.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
-$1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$3.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-4%
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$7.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
20%
|
CAGR 10-Years
5%
|
See Also
What is Anebulo Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-11.7m
USD
Based on the financial report for Jun 30, 2023, Anebulo Pharmaceuticals Inc's Pre-Tax Income amounts to -11.7m USD.
What is Anebulo Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-310%
Over the last year, the Pre-Tax Income growth was -72%. The average annual Pre-Tax Income growth rates for Anebulo Pharmaceuticals Inc have been -310% over the past three years .